Cutaneous T-Cell Lymphoma (CTCL) Recruiting Phase 1 / 2 Trials for Durvalumab (DB11714)

Also known as: Lymphoma, Cutaneous T-Cell / Cutaneous T-Cell Lymphomas / Cutaneous T-Cell Lymphoma / Cutaneous lymphoma / Lymphoma, T-Cell, Cutaneous

IndicationStatusPhase
DBCOND0071861 (Cutaneous T-Cell Lymphoma (CTCL))Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02643303A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible CancersTreatment